dabogratinib
Generic: Dabogratinib·Code: TYRA-300
dabogratinib: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Tyra Biosciences, Inc. (TYRA) | Phase 2 |
Clinical Trials (1)
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)
FDA Decisions
FDA_MeetingFDA allowed the IND for TYRA-300 to proceed with a Phase 2 BEACH301 study in children with achondroplasia.(TYRA)
Frequently asked questions
Who is developing dabogratinib?
dabogratinib is being developed by Tyra Biosciences, Inc..
How many clinical trials involve dabogratinib?
BioSniper tracks 1 clinical trial involving dabogratinib.
What is dabogratinib's latest FDA decision?
The most recent tracked FDA decision for dabogratinib is FDA_Meeting for FDA allowed the IND for TYRA-300 to proceed with a Phase 2 BEACH301 study in children with achondroplasia., dated October 28, 2024.
Get deeper analysis on dabogratinib
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis